P. Flores

Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

G. Mills, G. Hortobagyi, L. Pusztai, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

E. Winer, G. Hortobagyi, D. Booser, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

G. Mills, G. Hortobagyi, L. Pusztai, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

E. Winer, G. Hortobagyi, D. Booser, 2010 .